Important Update to Shareholders: Share Consolidation Clarification
Share consolidation has commenced, and the temporary ASX ticker is MDCDA. DA is a deferred account used whilst the shares are being consolidated. Market opening 5th Aug 2022, expectations are consolidated shares will revert back to MDC
NanaBisTM - Now With Synthetic CBD and THC
Following the company’s transformation to a pureplay biotech, Medlab Clinical has focused on the development of key asset NanaBis, a 50:50 micellar formulation of CBD and THC, in the treatment of cancer-induced bone pain.
Medlab proposes DUAL LISTING to the U.S. Nasdaq Stock Market
Medlab Clinical Ltd (ASX:MDC) welcomes all shareholders to exercise their voting rights at Extraordinary General Meeting scheduled for 28th July 2022.
Transforming into a pure-play biotech
With lead product NanaBis™ (NanoCelle® encapsulated 50:50 THC:CBD for pain) preparing to enter a Phase III trial in pain, management has decided to fully focus on therapeutics development and divested its nutraceuticals portfolio
Government grant to apply NanoCelle® to an RNA nasal vaccine
Medlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemics.
Global Investor News March 2022
Bimonthly Medlab news. This month: a note from our CEO, a research note from Morgan’s and UK NanaBis and NanoCBD.
Annual Message to Shareholders October 2021
Once Medlab Clinical’s listing on the ASX six years ago its experienced team of scientists have made extraordinary advances in the creation and manufacture of unique, world-leading products and valuable intellectual property.
Medlab mixes reality with Microsoft
Read the three featured stories from Microsoft about Medlab's adoption of mixed reality solutions including HoloLens 2 head-mounted devices with Dynamics 365
NanaBis demonstrates continued improvement in pain scores
The first cohort of Observational Study patients completing 12-month treatment with NanaBis™ demonstrated continued improvement in pain scores.
Medlab to be granted European patent for NanoCelle® drug delivery platform
European Patent Office issues Notice of Intention to grant Medlab Clinical patent for NanoCelle® drug delivery platform
Novartis’ Managing Director of Oncology (ANZ/NZ) joins Medlab Clinical board
Medlab Clinical appoints Novartis' Managing Director of Oncology for Australia and New Zealand as Non-Executive Director.
Medlab Clinical raises $15 million and Leading Executive Joins Board
Medlab Clinical successfully raised $15 million via a two-tranche placement.